Bio-Gene Targets 2027 APVMA Filing as Flavocide Toxicology Program Advances

Bio-Gene Technology Ltd. ( (AU:BGT) ) has issued an update.

Bio-Gene Technology has reported solid progress in the regulatory development of its novel insecticidal active constituent, Flavocide, with a series of toxicology and metabolism studies advancing according to plan. Early toxicology data have been sufficient to move into major reproductive and neurotoxicity studies, which are expected to deliver results in mid and late 2026.

The company is targeting March 2027 for its first submission to the Australian Pesticides & Veterinary Medicines Authority to register Flavocide as a new active constituent, initially to support professional and domestic insecticide products rather than food-related uses. Data are being generated to OECD standards to facilitate subsequent filings in the U.S. and other key markets, marking a critical milestone in commercialising Bio-Gene’s technology and potentially strengthening its competitive position in the insecticide industry.

The most recent analyst rating on (AU:BGT) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Bio-Gene Technology Ltd. stock, see the AU:BGT Stock Forecast page.

More about Bio-Gene Technology Ltd.

Bio-Gene Technology Ltd is an Australian biotechnology company focused on developing next-generation insecticides derived from natural compounds. Its lead active constituent, Flavocide, features a new mode of action and is being positioned for use in professional and domestic insecticide products, including applications such as mosquito control and other disease-vector flying insects.

Average Trading Volume: 103,269

Technical Sentiment Signal: Hold

Current Market Cap: A$10.07M

For an in-depth examination of BGT stock, go to TipRanks’ Overview page.